ResearcherMayo ClinicActive in the last 2 years
Kenneth Wing Merrell
Matched on ORCID iD 0000-0002-3831-5644; OpenAlex author ID A5088854603. Sources: ClinicalTrials.gov.
Their work
- Papers
- 4
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 35
2016: 1 paper · 2017: none · 2018: 1 trial · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper
Papers 4
- Determining the Minimal Clinically Important Difference of the Functional Assessment of Cancer Therapy Hepatobiliary Questionnaire to Evaluate the Change in th… Co-author DOI 10.1016/j.ijrobp.2023.08.009↗
- FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7041↗
- Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13205168↗
- Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2015.11.003↗
Trials 1
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christopher Leigh Hallemeier · 3 shared papers, 2016–2024 · strength 0.38
- Paper Determining the Minimal Clinically Important Difference of the Functional Assessment of Cancer Therapy Hepatobiliary Qu… DOI 10.1016/j.ijrobp.2023.08.009↗
- Paper FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenoca… DOI 10.6004/jnccn.2022.7041↗
- Paper Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer. DOI 10.1016/j.ijrobp.2015.11.003↗
- Michael G. Haddock · 3 shared papers, 2016–2024 · strength 0.38
- Paper Determining the Minimal Clinically Important Difference of the Functional Assessment of Cancer Therapy Hepatobiliary Qu… DOI 10.1016/j.ijrobp.2023.08.009↗
- Paper FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenoca… DOI 10.6004/jnccn.2022.7041↗
- Paper Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer. DOI 10.1016/j.ijrobp.2015.11.003↗
- Krishan R. Jethwa · 1 shared trial, 2018 · strength 0.20
- Terence T. Sio · 1 shared trial, 2018 · strength 0.20
- Isabella Zaniletti · 1 shared paper, 2024 · strength 0.20
- Todd A. DeWees · 1 shared paper, 2024 · strength 0.20
- Michael L. Kendrick · 2 shared papers, 2016–2022 · strength 0.18
- Paper FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenoca… DOI 10.6004/jnccn.2022.7041↗
- Paper Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer. DOI 10.1016/j.ijrobp.2015.11.003↗
- Thorvardur Ragnar Halfdanarson · 1 shared paper, 2022 · strength 0.12
- Amro M. Abdelrahman · 1 shared paper, 2022 · strength 0.12
- Jennifer A. Yonkus · 1 shared paper, 2022 · strength 0.12
- Sean Patrick Cleary · 1 shared paper, 2022 · strength 0.12
- Jennifer L. Leiting · 1 shared paper, 2022 · strength 0.12
- Nguyen H. Tran · 1 shared paper, 2022 · strength 0.12
- Travis Edward Grotz · 1 shared paper, 2022 · strength 0.12
- Rondell Patrell Graham · 1 shared paper, 2022 · strength 0.12
- Roberto Alva‐Ruiz · 1 shared paper, 2022 · strength 0.12
- Susanne Gray Warner · 1 shared paper, 2022 · strength 0.12
- Cornelius A. Thiels · 1 shared paper, 2022 · strength 0.12
- Mark Joseph Truty · 1 shared paper, 2022 · strength 0.12
- Wen Wee Ma · 1 shared paper, 2022 · strength 0.12
- Robert R. McWilliams · 1 shared paper, 2022 · strength 0.12
- Ajit Harishkumar Goenka · 1 shared paper, 2022 · strength 0.12
- Lizhi Zhang · 1 shared paper, 2021 · strength 0.11
- Adam R. Wolfe · 1 shared paper, 2021 · strength 0.11
- Nikhil Sebastian · 1 shared paper, 2021 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.